California’s Cosmetic Animal-Testing Ban Not A Brick Wall, But Proceed With Caution

Animal testing permitted for ingredients in Europe with purposes beyond cosmetics is not necessarily something that would forfeit products’ marketability in California under its Cruelty-Free Cosmetics Act. However, industry should seek guidance on the law’s interpretation from the state’s attorney general.

woman punching hole through paper wall with fist

Industry would be well-served to seek guidance from the California Attorney General on compliance with the state’s recently enacted Cruelty-Free Cosmetics Act, but the statute isn’t necessarily a death knell for cosmetic ingredient innovation.

In an Oct. 16 interview, Greg Sperla, an attorney in DLA Piper’s Sacramento, Calif. Office, said he believes the enforcement...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By 

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

US Tariff Exemption For Indonesian Materials Not Produced Domestically A Boon For Fragrance – FCA

 

The Fragrance Creators Association President & CEO Farah Ahmed commends the Trump Administration for exempting from tariffs Indonesian goods not naturally available or produced in the US, which recognizes the “essential” role of fragrance and essential oils.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.